Genetic variants in C5 and poor response to eculizumab.
暂无分享,去创建一个
J. Inazawa | K. Ando | Y. Kanakura | T. Kinoshita | K. Ohyashiki | Toru Takahashi | H. Noji | H. Shibayama | M. Masuko | Krista Johnson | P. Tamburini | T. Eto | Shin Hayashi | Takuro Matsumoto | K. Kitamura | Y. Wano | T. Shichishima | J. Nishimura | A. Lazarowski | A. Brodsky | M. Hase | Masaki Yamamoto | Lan Li
[1] V. Frémeaux-Bacchi,et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies , 2012, Nature Reviews Nephrology.
[2] L. Luzzatto,et al. Management of Paroxysmal Nocturnal Haemoglobinuria: a personal view , 2011, British journal of haematology.
[3] N. S. Laursen,et al. Substrate recognition by complement convertases revealed in the C5–cobra venom factor complex , 2011, The EMBO journal.
[4] K. Ozawa,et al. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS Clinical Trial , 2011, International journal of hematology.
[5] R. Brodsky. How I treat paroxysmal nocturnal hemoglobinuria. , 2009, Blood.
[6] A. Zanella,et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. , 2009, Blood.
[7] C. Parker. Eculizumab for paroxysmal nocturnal haemoglobinuria , 2009, The Lancet.
[8] N. Young,et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. , 2008, Blood.
[9] N. Young,et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. , 2007, Blood.
[10] R. Brodsky,et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria , 2007, Nature Biotechnology.
[11] N. Young,et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. , 2006, The New England journal of medicine.
[12] Neal Young,et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. , 2005, Blood.
[13] S. Richards,et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. , 2005, Blood.
[14] E. Kimby,et al. Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Hall,et al. Clinical Course and Flow Cytometric Analysis of Paroxysmal Nocturnal Hemoglobinuria in the United States and Japan , 2004, Medicine.
[16] S. Richards,et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. , 2004, The New England journal of medicine.
[17] G. Salles,et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.
[18] C. Berg. Purification of complement components, regulators, and receptors by classical methods. , 2000 .
[19] R. Kimberly,et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. , 1997, The Journal of clinical investigation.
[20] J. Mary,et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors , 1996, The Lancet.
[21] S M Lewis,et al. Natural history of paroxysmal nocturnal hemoglobinuria. , 1995, The New England journal of medicine.
[22] T. Miyata,et al. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. , 1994, The New England journal of medicine.
[23] Teizo Fujita,et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria , 1993, Cell.
[24] T. Miyata,et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. , 1993, Science.
[25] M. Oppermann,et al. Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. , 1991, Complement and inflammation.